Randomized Controlled Trial
. 2006 Sep 7;355(10):983-91. doi: 10.1056/NEJMoa060570. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy Ariane Dunant, Pierre Fouret, Elisabeth Brambilla, Fabrice André, Vincent Haddad, Estelle Taranchon, Martin Filipits, Robert Pirker, Helmut H Popper, Rolf Stahel, Laure Sabatier, Jean-Pierre Pignon, Thomas Tursz, Thierry Le Chevalier, Jean-Charles Soria; IALT Bio InvestigatorsAffiliations
AffiliationItem in Clipboard
Randomized Controlled Trial
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapyKen A Olaussen et al. N Engl J Med. 2006.
Free article . 2006 Sep 7;355(10):983-91. doi: 10.1056/NEJMoa060570. Authors Ken A Olaussen 1 , Ariane Dunant, Pierre Fouret, Elisabeth Brambilla, Fabrice André, Vincent Haddad, Estelle Taranchon, Martin Filipits, Robert Pirker, Helmut H Popper, Rolf Stahel, Laure Sabatier, Jean-Pierre Pignon, Thomas Tursz, Thierry Le Chevalier, Jean-Charles Soria; IALT Bio Investigators AffiliationItem in Clipboard
AbstractBackground: Adjuvant cisplatin-based chemotherapy improves survival among patients with completely resected non-small-cell lung cancer, but there is no validated clinical or biologic predictor of the benefit of chemotherapy.
Methods: We used immunohistochemical analysis to determine the expression of the excision repair cross-complementation group 1 (ERCC1) protein in operative specimens of non-small-cell lung cancer. The patients had been enrolled in the International Adjuvant Lung Cancer Trial, thereby allowing a comparison of the effect of adjuvant cisplatin-based chemotherapy on survival, according to ERCC1 expression. Overall survival was analyzed with a Cox model adjusted for clinical and pathological factors.
Results: Among 761 tumors, ERCC1 expression was positive in 335 (44%) and negative in 426 (56%). A benefit from cisplatin-based adjuvant chemotherapy was associated with the absence of ERCC1 (test for interaction, P=0.009). Adjuvant chemotherapy, as compared with observation, significantly prolonged survival among patients with ERCC1-negative tumors (adjusted hazard ratio for death, 0.65; 95% confidence interval [CI], 0.50 to 0.86; P=0.002) but not among patients with ERCC1-positive tumors (adjusted hazard ratio for death, 1.14; 95% CI, 0.84 to 1.55; P=0.40). Among patients who did not receive adjuvant chemotherapy, those with ERCC1-positive tumors survived longer than those with ERCC1-negative tumors (adjusted hazard ratio for death, 0.66; 95% CI, 0.49 to 0.90; P=0.009).
Conclusions: Patients with completely resected non-small-cell lung cancer and ERCC1-negative tumors appear to benefit from adjuvant cisplatin-based chemotherapy, whereas patients with ERCC1-positive tumors do not.
Copyright 2006 Massachusetts Medical Society.
Similar articlesXie KJ, He HE, Sun AJ, Liu XB, Sun LP, Dong XJ. Xie KJ, et al. Asian Pac J Cancer Prev. 2014;15(6):2591-6. doi: 10.7314/apjcp.2014.15.6.2591. Asian Pac J Cancer Prev. 2014. PMID: 24761869
Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N. Booton R, et al. J Thorac Oncol. 2007 Oct;2(10):902-6. doi: 10.1097/JTO.0b013e318155a637. J Thorac Oncol. 2007. PMID: 17909351 Clinical Trial.
Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, André F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria JC. Friboulet L, et al. N Engl J Med. 2013 Mar 21;368(12):1101-10. doi: 10.1056/NEJMoa1214271. N Engl J Med. 2013. PMID: 23514287 Free PMC article.
Olaussen KA, Mountzios G, Soria JC. Olaussen KA, et al. Curr Opin Pulm Med. 2007 Jul;13(4):284-9. doi: 10.1097/MCP.0b013e32816b5c63. Curr Opin Pulm Med. 2007. PMID: 17534174 Review.
Rosell R, Cobo M, Isla D, Sanchez JM, Taron M, Altavilla G, Santarpia M, Moran T, Catot S, Etxaniz O. Rosell R, et al. Lung Cancer. 2005 Dec;50 Suppl 2:S33-40. Lung Cancer. 2005. PMID: 16557672 Review.
de Mello RA, Pires FS, Marques DS, Oliveira J, Rodrigues A, Soares M, Azevedo I, Peixoto A, Santos C, Pinto C, Hespanhol V, Teixeira MR, Amaro T, Queiroga H, Araújo A. de Mello RA, et al. Tumour Biol. 2012 Dec;33(6):2061-8. doi: 10.1007/s13277-012-0465-5. Epub 2012 Jul 29. Tumour Biol. 2012. PMID: 22843317
Yan D, Wei P, An G, Chen W. Yan D, et al. J Cardiothorac Surg. 2013 Jun 10;8:149. doi: 10.1186/1749-8090-8-149. J Cardiothorac Surg. 2013. PMID: 23759026 Free PMC article.
Wang YY, Fang PT, Su CW, Chen YK, Huang JJ, Huang MY, Yuan SF. Wang YY, et al. Oncol Lett. 2021 Jun;21(6):450. doi: 10.3892/ol.2021.12711. Epub 2021 Apr 7. Oncol Lett. 2021. PMID: 33868488 Free PMC article.
Dong H, Bao D, Guo X, Hu J, Li X, Wan S, Xing J. Dong H, et al. Tumour Biol. 2015 Sep;36(9):7151-7. doi: 10.1007/s13277-015-3447-6. Epub 2015 Apr 16. Tumour Biol. 2015. PMID: 25877757
Mu Y, Dong Y, Zheng M, Barr MP, Roviello G, Hu Z, Liu J. Mu Y, et al. J Thorac Dis. 2024 Jul 30;16(7):4567-4583. doi: 10.21037/jtd-24-827. Epub 2024 Jul 26. J Thorac Dis. 2024. PMID: 39144297 Free PMC article.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3